Cargando…

Management of Pediatric Strokes With Alteplase (Tissue Plasminogen Activator)

In the pediatric population, ischemic stroke is rare. Pediatric patients with acute ischemic stroke are eligible for intravenous thrombolysis and/or mechanical thrombectomy. However, due to the rare occurrence of strokes and national shortage of pediatric neurologists, timely diagnosis and appropria...

Descripción completa

Detalles Bibliográficos
Autores principales:	Filatov, Asia, Alvarez, Jaime, Seibert, Jessica, Swerdloff, Marc
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cureus 2021
Materias:	Neurology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8431982/ https://www.ncbi.nlm.nih.gov/pubmed/34527475 http://dx.doi.org/10.7759/cureus.17088

Ejemplares similares

Ziprasidone-Induced Oculogyric Crisis in a 74-Year-Old Female
por: Wilson, Alphonso, et al.
Publicado: (2020)

Silver Jubilee of Stroke Thrombolysis With Alteplase: Evolution of the Therapeutic Window
por: Pan, Yuanmei, et al.
Publicado: (2021)

The budget impact of alteplase in the treatment of acute ischemic stroke in Egypt
por: Aref, Hany, et al.
Publicado: (2023)

Tissue plasminogen activator and patients with acute ischemic stroke: The litigation landscape
por: Ganti, Latha, et al.
Publicado: (2022)

Thrombotic Thrombocytopenic Purpura Masquerading as Acute Ischemic Stroke
por: Filatov, Asia, et al.
Publicado: (2020)

Probing the Effective Treatment Thresholds for Alteplase in Acute Ischemic Stroke With Regression Discontinuity Designs
por: Naidech, Andrew M., et al.
Publicado: (2020)

Machine Learning-Based Model for Prediction of Hemorrhage Transformation in Acute Ischemic Stroke After Alteplase
por: Xu, Yanan, et al.
Publicado: (2022)

A Comparative Study of Hemorrhagic Conversion Patterns After Stroke Thrombolysis With Alteplase Versus Tenecteplase
por: Ezzeldin, Mohamad, et al.
Publicado: (2023)

Impact of Intravenous Alteplase Door-to-Needle Times on 2-Year Mortality in Patients With Acute Ischemic Stroke
por: Bhatt, Nirav R., et al.
Publicado: (2021)

Association of White Blood Cell Count With Clinical Outcome Independent of Treatment With Alteplase in Acute Ischemic Stroke
por: Barow, Ewgenia, et al.
Publicado: (2022)

Low-dose vs. standard-dose intravenous alteplase for acute ischemic stroke with unknown time of onset
por: Wang, Zekun, et al.
Publicado: (2023)

Different Doses of Intravenous Tissue-Type Plasminogen Activator for Acute Ischemic Stroke: A Network Meta-Analysis
por: Li, Bing-Hu, et al.
Publicado: (2022)

Tenecteplase vs. alteplase for treatment of acute ischemic stroke: A systematic review and meta-analysis of randomized trials
por: Kobeissi, Hassan, et al.
Publicado: (2023)

The use of alteplase, although safe, does not offer clear clinical advantages when mild stroke is non-disabling
por: Merlino, Giovanni, et al.
Publicado: (2023)

A Canine Model of Hemorrhagic Transformation Using Recombinant Tissue Plasminogen Activator Administration After Acute Ischemic Stroke
por: Jiang, Run-Hao, et al.
Publicado: (2019)

Comparing the Effectiveness of Intravenous Tissue Plasminogen Activator and Dual Antiplatelet Therapy in Patients With Minor Stroke: A Meta-Analysis
por: Monday, Obinna, et al.
Publicado: (2023)

Tenecteplase versus Alteplase for Stroke Thrombolysis Evaluation Trial in the Ambulance (Mobile Stroke Unit—TASTE-A): protocol for a prospective randomised, open-label, blinded endpoint, phase II superiority trial of tenecteplase versus alteplase for ischaemic stroke patients presenting within 4.5 hours of symptom onset to the mobile stroke unit
por: Bivard, Andrew, et al.
Publicado: (2022)

Effectiveness of Standard-Dose vs. Low-Dose Alteplase for Acute Ischemic Stroke Within 3–4.5 h
por: Chen, Chih-Hao, et al.
Publicado: (2022)

Low-dose vs. standard-dose alteplase for Chinese patients with acute ischemic stroke: A propensity score analysis
por: Xu, Jiawen, et al.
Publicado: (2023)

Low-Dose vs. Standard-Dose Intravenous Alteplase in Bridging Therapy Among Patients With Acute Ischemic Stroke: Experience From a Stroke Center in Vietnam
por: Mai, Duy Ton, et al.
Publicado: (2021)

A Case of Steroid-Responsive Encephalopathy
por: Kondramashin, Alona, et al.
Publicado: (2021)

Factors associated with functional disability in patients with acute stroke excluded from alteplase administration due to minor non-disabling neurological deficits
por: Kim, Yong Jin, et al.
Publicado: (2022)

Mechanical Thrombectomy With and Without Intravenous Tissue Plasminogen Activator for Acute Ischemic Stroke: A Systematic Review and Meta-Analysis Using Nested Knowledge
por: Adusumilli, Gautam, et al.
Publicado: (2021)

No sex difference was found in the safety and efficacy of intravenous alteplase before endovascular therapy
por: Fang, Min, et al.
Publicado: (2022)

Parkinson's Disease: Unanticipated Sequela of an Attempted Suicide
por: Grossman, Jonathan T, et al.
Publicado: (2020)

Outcome of Delayed Administration of Alteplase in a Resource-Poor Area: A Case Report
por: Idowu, Ahmed O, et al.
Publicado: (2022)

Leber Hereditary Optic Neuropathy: Case Report and Literature Review
por: Filatov, Asia, et al.
Publicado: (2020)

Cost-effectiveness of recombinant tissue-type plasminogen activator for acute ischaemic stroke with unknown time of onset: a Markov modelling analysis from the Chinese and US perspectives
por: Zhao, Songfeng, et al.
Publicado: (2022)

Correlation Between Blood Glucose Variability and Early Therapeutic Effects After Intravenous Thrombolysis With Alteplase and Levels of Serum Inflammatory Factors in Patients With Acute Ischemic Stroke
por: Cai, Yun, et al.
Publicado: (2022)

Dissolution Effect of Alteplase on Arterial Blood Clot Model of Hypertensive Intracerebral Hemorrhage Patients in vitro
por: Jiang, Xiaoming, et al.
Publicado: (2022)

Neurological Complications of Coronavirus Disease (COVID-19): Encephalopathy
por: Filatov, Asia, et al.
Publicado: (2020)

Different doses of tenecteplase vs. alteplase for acute ischemic stroke within 4.5 hours of symptom onset: a network meta-analysis of randomized controlled trials
por: Liang, Huo, et al.
Publicado: (2023)

Transvenous Catheter-Based Thrombolysis With Continuous Tissue Plasminogen Activator Infusion for Refractory Thrombosis in a Patient With Behcet’s Disease
por: Arif, Saeed, et al.
Publicado: (2020)

Tissue-Type Plasminogen Activator and Tenecteplase-Mediated Increase in Blood Brain Barrier Permeability Involves Cell Intrinsic Complement
por: Keragala, Charithani B., et al.
Publicado: (2020)

MUlticenter STudy of tissue plasminogen activator (alteplase) use in COVID‐19 severe respiratory failure (MUST COVID): A retrospective cohort study
por: Barrett, Christopher D., et al.
Publicado: (2022)

Intravenous Tissue Plasminogen Activator in Combination With Mechanical Thrombectomy: Clot Migration, Intracranial Bleeding, and the Impact of “Drip and Ship” on Effectiveness and Outcomes
por: Chang, Adam, et al.
Publicado: (2020)

POEMS (Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal Gammopathy, and Skin Changes) Syndrome Masquerading as Chronic Inflammatory Polyradiculoneuropathy: A Case Report
por: Bayas, Angel, et al.
Publicado: (2022)

Clinical Diagnosis of Temporal Arteritis With Seronegative and Negative Biopsy Studies
por: Bayas, Angel, et al.
Publicado: (2022)

Effects of alteplase in the treatment of acute ischemic stroke
por: Yayan, Josef
Publicado: (2012)

The Development of Pulmonary Edema after Recombinant Tissue Plasminogen Activator in Acute Ischemic Stroke Patient; Neurogenic or Non-Neurogenic?
por: Alwahdy, Ahmad Sulaiman, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_uia1k573sum256hkfng80bln2i